Literature DB >> 18154545

Sulbactam-containing beta-lactamase inhibitor combinations.

M Akova1.   

Abstract

Sulbactam irreversibly inhibits the hydrolytic activity of beta-lactamases. This compound is commercially available in combination with either ampicillin or cefoperazone. In each instance, the activity of the partner antibiotic against beta-lactamase-producing bacteria is restored. One of the particular advantages of using sulbactam-containing combinations is that sulbactam itself has inherent activity against some Acinetobacter baumannii. Sulbactam combinations have not demonstrated strong selective pressures for extended-spectrum beta-lactamase-producing Enterobacteriaceae and vancomycin-resistant enterococci. In contrast to clavulanate, sulbactam does not induce class I (Ampc) chromosomal beta-lactamases in Enterobacteriaceae.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18154545     DOI: 10.1111/j.1469-0691.2007.01847.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  14 in total

1.  Clinical characteristics of bloodstream infections due to ampicillin-sulbactam-resistant, non-extended- spectrum-beta-lactamase-producing Escherichia coli and the role of TEM-1 hyperproduction.

Authors:  Rebecca I Waltner-Toews; David L Paterson; Zubair A Qureshi; Hanna E Sidjabat; Jennifer M Adams-Haduch; Kathleen A Shutt; Mark Jones; Guo-Bao Tian; Anthony W Pasculle; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

Review 2.  The future of the β-lactams.

Authors:  Leticia I Llarrull; Sebastian A Testero; Jed F Fisher; Shahriar Mobashery
Journal:  Curr Opin Microbiol       Date:  2010-09-29       Impact factor: 7.934

3.  Molecular Insights on the Release of Avibactam from the Acyl-Enzyme Complex.

Authors:  Ignacio Lizana; Eduardo J Delgado
Journal:  Biophys J       Date:  2019-04-02       Impact factor: 4.033

Review 4.  Recent Developments to Cope the Antibacterial Resistance via β-Lactamase Inhibition.

Authors:  Zafar Iqbal; Jian Sun; Haikang Yang; Jingwen Ji; Lili He; Lijuan Zhai; Jinbo Ji; Pengjuan Zhou; Dong Tang; Yangxiu Mu; Lin Wang; Zhixiang Yang
Journal:  Molecules       Date:  2022-06-14       Impact factor: 4.927

Review 5.  Three decades of beta-lactamase inhibitors.

Authors:  Sarah M Drawz; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

6.  Homology modeling and virtual screening approaches to identify potent inhibitors of VEB-1 β-lactamase.

Authors:  Abdelmonaem Messaoudi; Hatem Belguith; Jeannette Ben Hamida
Journal:  Theor Biol Med Model       Date:  2013-04-02       Impact factor: 2.432

7.  Clinical Outcomes and Adverse Effects in Septic Patients with Impaired Renal Function Who Received Different Dosages of Cefoperazone-Sulbactam.

Authors:  Chien-Hsiang Tai; Hung-Jen Tang; Chen-Hsiang Lee
Journal:  Antibiotics (Basel)       Date:  2022-03-29

Review 8.  N-Propargylamines: versatile building blocks in the construction of thiazole cores.

Authors:  S Arshadi; E Vessally; L Edjlali; R Hosseinzadeh-Khanmiri; E Ghorbani-Kalhor
Journal:  Beilstein J Org Chem       Date:  2017-03-30       Impact factor: 2.883

9.  A multicentre clinical study on the injection of ceftriaxone/sulbactam compared with cefoperazone/sulbactam in the treatment of respiratory and urinary tract infections.

Authors:  Xiaojuan Xin; Li Jian; Xiaoying Xia; Bei Jia; Wenxiang Huang; Chongzhi Li; Changzheng Wang; Lixin Zhou; Xiuzhen Sun; Xinghuo Tang; Yijiang Huang; Yunkui Zhu; Weili Zhang
Journal:  Ann Clin Microbiol Antimicrob       Date:  2013-12-09       Impact factor: 3.944

Review 10.  Production of β-Lactamase Inhibitors by Streptomyces Species.

Authors:  Daniela de Araújo Viana Marques; Suellen Emilliany Feitosa Machado; Valéria Carvalho Santos Ebinuma; Carolina de Albuquerque Lima Duarte; Attilio Converti; Ana Lúcia Figueiredo Porto
Journal:  Antibiotics (Basel)       Date:  2018-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.